Dimerix Limited reported earnings results for the full year ended June 30, 2023. For the full year, the company reported net loss was AUD 13.8 million compared to AUD 10.49 million a year ago. Basic loss per share from continuing operations was AUD 0.0424 compared to AUD 0.0356 a year ago.
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
0.54 AUD | +10.20% | +35.00% | +163.41% |
May. 29 | Euroz Hartleys Adjusts Dimerix’s Price Target to AU$0.86 From AU$0.80, Keeps at Speculative Buy | MT |
May. 27 | Dimerix Signs License Deal for Kidney Disease Medication in the Middle East | MT |
1st Jan change | Capi. | |
---|---|---|
+163.41% | 179M | |
+57.44% | 59.34B | |
+43.17% | 40.24B | |
-4.87% | 39.88B | |
-5.56% | 28.55B | |
+14.95% | 27.26B | |
-21.09% | 19.23B | |
+32.60% | 12.61B | |
+2.42% | 12.49B | |
+25.92% | 12.28B |
- Stock Market
- Equities
- DXB Stock
- News Dimerix Limited
- Dimerix Limited Reports Earnings Results for the Full Year Ended June 30, 2023